Basilea Pharmaceutica (Switzerland) Today

BSLN Stock  CHF 42.10  0.80  1.94%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 33

 
High
 
Low
Below Average
Basilea Pharmaceutica is selling for under 42.10 as of the 26th of November 2024; that is 1.94 percent increase since the beginning of the trading day. The stock's lowest day price was 40.95. Basilea Pharmaceutica has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Basilea Pharmaceutica AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of July 2023 and ending today, the 26th of November 2024. Click here to learn more.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company was founded in 2000 and is headquartered in Basel, Switzerland. The company has 11.93 M outstanding shares. More on Basilea Pharmaceutica AG

Moving together with Basilea Stock

  0.74IDIA IdorsiaPairCorr

Moving against Basilea Stock

  0.62RLF Relief TherapeuticsPairCorr
  0.53GALE Galenica Sante AGPairCorr
  0.41MOLN Molecular PartnersPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Basilea Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Basilea Pharmaceutica's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Basilea Pharmaceutica or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Business ConcentrationBiotechnology, Healthcare (View all Sectors)
Basilea Pharmaceutica AG (BSLN) is traded on SIX Swiss Exchange in Switzerland and employs 177 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 591.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Basilea Pharmaceutica's market, we take the total number of its shares issued and multiply it by Basilea Pharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Basilea Pharmaceutica operates under Healthcare sector and is part of Biotechnology industry. The entity has 11.93 M outstanding shares. Basilea Pharmaceutica AG has accumulated about 0 in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.81.
Check Basilea Pharmaceutica Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Basilea Pharmaceutica is ₣591.36 Million. Basilea Pharmaceutica AG shows 3.05 percent of its outstanding shares held by insiders and 28.93 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Basilea Ownership Details

Basilea Pharmaceutica Risk Profiles

Although Basilea Pharmaceutica's alpha and beta are two of the key measurements used to evaluate Basilea Pharmaceutica's performance over the market, the standard measures of volatility play an important role as well.

Basilea Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Basilea Pharmaceutica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
All  Next Launch Module

Basilea Pharmaceutica Corporate Management

Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.

Additional Tools for Basilea Stock Analysis

When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.